EcoDrugPlus

Cholecystokinin A Receptor

Ensembl ID : ENSCVAG00000006922
Gene Symbol: CCKAR
4 Cross references
201 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSCVAG00000018826
Gene Symbol: LOC107099853
2 Cross references
195 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSCVAG00000007879
Gene Symbol: LOC107086875
3 Cross references
198 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSCVAG00000012281
Gene Symbol: LOC107097647
2 Cross references
252 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSCVAG00000012379
Gene Symbol: LOC107097654
2 Cross references
253 Possible Orthologues:

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSCVAG00000002033
Gene Symbol: CETP
3 Cross references
151 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSCVAG00000016771
Gene Symbol: CHRM2
3 Cross references
196 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSCVAG00000000190
Gene Symbol: CHRM2
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSCVAG00000016022
Gene Symbol: CHRM3
3 Cross references
188 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSCVAG00000019070
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSCVAG00000020976
Gene Symbol: CHRNA7
3 Cross references
208 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSCVAG00000023298
Gene Symbol: CHRNB2
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).